NASDAQ:ROIV
Roivant Sciences Ltd.
Roivant Sciences Ltd.'s revenue fell 71.6% in fiscal 2025 to $8.3M while operating margin fell to −6235.7%, its lowest in 6 years. Free cash flow was −$758.6M, −9183.5% of revenue, and the diluted share count fell 4.3%.Summary generated from Roivant Sciences Ltd.'s SEC filings. Latest annual report filed May 20, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$8.3M
Revenue growth−71.6%
Revenue, 5-yr CAGR−19.1%
Gross marginn/a
Operating margin−6235.7%
Net margin−3629.2%
ROICn/a
Return on equity−6.5%
Debt / equityn/a
Free cash flow−$758.6M
FCF margin−9183.5%
Share count change−4.3%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 55 | 32 | 33 | 29 | 8 |
| Operating income | −1,352 | −907 | 4,497 | −1,003 | −515 |
| Net income | −845 | −1,009 | 4,349 | −172 | −300 |
| Free cash flow | −695 | −856 | −767 | −844 | −759 |
Recent filings
- 4Insider transaction report
Oct 5, 2026 - 4Insider transaction report
Oct 5, 2026 - 8-KResults of a shareholder vote
Sep 18, 2026 - 8-KRegulation FD disclosure
Sep 8, 2026 - 8-KOther events
Aug 28, 2026 - 8-KRegulation FD disclosure
Aug 27, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026